INT67597

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1996
Last Reported 2011
Negated 0
Speculated 1
Reported most in Body
Documents 17
Total Number 21
Disease Relevance 9.95
Pain Relevance 5.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Das (Mus musculus)
Pain Link Frequency Relevance Heat
Infliximab 132 99.92 Very High Very High Very High
Paracetamol 17 99.12 Very High Very High Very High
corticosteroid 23 99.04 Very High Very High Very High
methotrexate 82 99.00 Very High Very High Very High
rheumatoid arthritis 386 98.48 Very High Very High Very High
cytokine 255 98.04 Very High Very High Very High
Arthritis 142 96.44 Very High Very High Very High
long-term potentiation 26 96.16 Very High Very High Very High
Pain 52 94.72 High High
Rheumatism 4 93.92 High High
Disease Link Frequency Relevance Heat
Disease 254 100.00 Very High Very High Very High
Influenza Virus Infection 134 98.72 Very High Very High Very High
Rheumatoid Arthritis 436 98.48 Very High Very High Very High
Hepatotoxicity 6 97.32 Very High Very High Very High
Infection 64 97.00 Very High Very High Very High
Arthritis 27 96.44 Very High Very High Very High
Seronegative Spondarthritis 112 96.34 Very High Very High Very High
Skin Diseases 12 94.60 High High
Rheumatic Diseases 7 93.92 High High
Adverse Drug Reaction 3 93.32 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
DAS decreased slightly with no statistically significant differences between the groups.
Negative_regulation (decreased) of DAS
1) Confidence 0.37 Published 2006 Journal Clin. Exp. Rheumatol. Section Body Doc Link 16870097 Disease Relevance 0.28 Pain Relevance 0
As the effect of DAS on APAP-induced hepatotoxicity in vivo was observed only when DAS was administered before or shortly after (< 3 hr) APAP dosing, data suggested that the protective effect of DAS is mainly at the metabolic activation step of APAP.
Negative_regulation (effect) of DAS associated with paracetamol and hepatotoxicity
2) Confidence 0.34 Published 1996 Journal Food Chem. Toxicol. Section Abstract Doc Link 9012771 Disease Relevance 0.52 Pain Relevance 1.05
In our present study, a significant reduction in Disease Activity Score (DAS) was observed following antioxidant intervention of 10 weeks.
Negative_regulation (reduction) of DAS associated with disease
3) Confidence 0.32 Published 2008 Journal Clin Rheumatol Section Body Doc Link PMC2367388 Disease Relevance 0.79 Pain Relevance 0.20
This was shown by a significantly decreased DAS (?
Negative_regulation (decreased) of DAS
4) Confidence 0.32 Published 2008 Journal Clin Rheumatol Section Body Doc Link PMC2367388 Disease Relevance 0.46 Pain Relevance 0.14
The reduction of DAS is remarkable as all patients had an active (high initial mean DAS of 5.8) longstanding disease and had tried all kinds of disease-modifying anti-rheumatic drugs, including combination therapy.
Negative_regulation (reduction) of DAS associated with disease
5) Confidence 0.24 Published 2008 Journal Clin Rheumatol Section Body Doc Link PMC2367388 Disease Relevance 0.72 Pain Relevance 0.15
Experience in a set of memory tasks, involving tests of reference, working and associative memory in the Morris water maze, lead to an increase in the mRNA expression of the GluN10XX (1-a) splice variants in old mice only, but exacerbated the age-related decrease in GluN1X10 (1-3) splice variant mRNA densities (Das and Magnusson, 2008).
Negative_regulation (decrease) of Das
6) Confidence 0.08 Published 2010 Journal Frontiers in Aging Neuroscience Section Body Doc Link PMC2874396 Disease Relevance 0.25 Pain Relevance 0.09
For dichotomous analysis response was determined as a decrease in DAS28 of ?
Spec (determined) Negative_regulation (decrease) of DAS28
7) Confidence 0.04 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564787 Disease Relevance 0.09 Pain Relevance 0.05
The majority of patients in this study were responding to therapy, as shown by their decreases in DAS (?
Negative_regulation (decreases) of DAS
8) Confidence 0.04 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2724743 Disease Relevance 0 Pain Relevance 0.15
We have previously observed that NAIs, oseltamivir and zanamivir, do not inhibit DAS181 activity in vitro or in vivo (unpublished data).
Negative_regulation (inhibit) of DAS181
9) Confidence 0.03 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2770640 Disease Relevance 0.85 Pain Relevance 0.10
At 24 weeks 16 of the 24 patients (67%) had a decrease in DAS28 of at least 1.2.
Negative_regulation (decrease) of DAS28
10) Confidence 0.03 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564787 Disease Relevance 0.06 Pain Relevance 0.07
The DAS28 was unaltered at 4 weeks (peri-infusional corticosteroids were not allowed), but there was a significant decrease in DAS28 at 16 and 24 weeks (compared to baseline: mean (SD) decrease of 1.6 (1.1) and 1.6 (1.6), respectively; both p<0.001).
Negative_regulation (decrease) of DAS28 associated with corticosteroid
11) Confidence 0.03 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564787 Disease Relevance 0.06 Pain Relevance 0.08
Parameters that were significantly related to the decrease in DAS28 were subsequently analysed by univariate linear regression analysis to assess the predictive value.
Negative_regulation (decrease) of DAS28
12) Confidence 0.03 Published 2008 Journal Annals of the Rheumatic Diseases Section Body Doc Link PMC2564787 Disease Relevance 0.09 Pain Relevance 0.07
The effective inhibitory DAS181 concentration for the pandemic influenza A(H1N1) viruses was similar to that with seasonal IFV, suggesting that the pandemic influenza A(H1N1) viruses binds to sialic acid residues comparably recognized by DAS181.
Negative_regulation (inhibitory) of DAS181 associated with influenza virus infection
13) Confidence 0.02 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2770640 Disease Relevance 1.26 Pain Relevance 0
After each administration of infliximab, a decrease in DAS was observed that was sustained for approximately 6 weeks, after which the score slowly increased to approximately 75% of the baseline value until the next infusion.
Negative_regulation (decrease) of DAS associated with infliximab
14) Confidence 0.02 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC464872 Disease Relevance 0.37 Pain Relevance 0.56
Two weeks after the first infusion of infliximab a significant and clinically relevant decrease in DAS was observed.
Negative_regulation (decrease) of DAS associated with infliximab
15) Confidence 0.02 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC464872 Disease Relevance 0.61 Pain Relevance 0.28
The mean DAS was reduced from 6.0 ± 0.5 to 3.6 ± 0.6 (P ?
Negative_regulation (reduced) of DAS
16) Confidence 0.02 Published 2004 Journal Arthritis Res Ther Section Abstract Doc Link PMC464872 Disease Relevance 0.91 Pain Relevance 0.31
In comparison with previously performed clinical trials in PsA with 5 mg/kg infliximab [33], we demonstrated that a low-dose treatment regimen with 3 mg/kg in combination with stable methotrexate therapy was also efficacious, exhibiting a rapid decrease in both PASI and DAS after the first dose of infliximab.
Negative_regulation (decrease) of DAS associated with infliximab, methotrexate and arthritis
17) Confidence 0.02 Published 2004 Journal Arthritis Res Ther Section Body Doc Link PMC464872 Disease Relevance 0.33 Pain Relevance 0.46
The decrease in DAS28 was statistically significant based on the results of a Paired t-test (p = 0.013).
Negative_regulation (decrease) of DAS28
18) Confidence 0.02 Published 2011 Journal Yonsei Medical Journal Section Body Doc Link PMC3017685 Disease Relevance 0.24 Pain Relevance 0.17
After eight weeks of medical treatment in patients with high disease activity, a decrease in DAS28 was associated with a significant decrease in the serum concentrations of IL-6 and IL-11.


Negative_regulation (decrease) of DAS28 associated with disease
19) Confidence 0.02 Published 2011 Journal Yonsei Medical Journal Section Abstract Doc Link PMC3017685 Disease Relevance 1.02 Pain Relevance 0.47
Five patients who had high disease activity showed decreased DAS28 of less than 5.1 after the eight-week treatment.
Negative_regulation (decreased) of DAS28 associated with disease
20) Confidence 0.02 Published 2011 Journal Yonsei Medical Journal Section Body Doc Link PMC3017685 Disease Relevance 0.19 Pain Relevance 0.13

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox